Plavakeerthi Kemparajurs, MD
Family Medicine · la Grange, KYNPI 1750371969
Payments from drug & device makers
Across 283 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$747
- AstraZeneca$668
- Novo Nordisk$425
- Lilly USA, LLC$371
- GSK$292
- Pfizer$262
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,43098%
- Education$762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $747 |
| AstraZeneca | 39 | $668 |
| Novo Nordisk | 24 | $425 |
| Lilly USA, LLC | 23 | $371 |
| GSK | 23 | $292 |
| Pfizer | 17 | $262 |
| Boehringer Ingelheim | 15 | $239 |
| Esperion Therapeutics, Inc. | 14 | $223 |
| Merck | 11 | $198 |
| Novartis | 11 | $187 |
| Johnson & Johnson | 9 | $150 |
| Bayer | 4 | $83 |
| Amarin Pharma, Inc. | 4 | $69 |
| Amgen | 4 | $63 |
| Mylan Specialty L.p. | 3 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Sanofi Pasteur Inc. | 2 | $49 |
| Abbott | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Tolmar, Inc. | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Biodelivery Sciences International, Inc. | 1 | $15 |
| Halozyme Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
How this compares
$4,505 in reported general payments places this provider in the 80th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 122 | $158,979 |
| EliquisApixaban | 155 | $155,217 |
| JardianceEmpagliflozin | 88 | $100,679 |
| JanuviaSitagliptin Phosphate | 93 | $99,729 |
| TrulicityDulaglutide | 62 | $93,852 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $75,034 |
| XareltoRivaroxaban | 55 | $67,537 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $62,610 |
| Repatha SureclickEvolocumab | 42 | $45,420 |
| RybelsusSemaglutide | 30 | $39,729 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 29 | $37,961 |
| FarxigaDapagliflozin Propanediol | 21 | $32,284 |
| MounjaroTirzepatide | 17 | $32,243 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $28,470 |
| LinzessLinaclotide | 22 | $26,295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $425 | $198,708152 claims |
| PfizerEliquis | $262 | $155,217155 claims |
| MerckJanuvia, Janumet Xr | $198 | $137,690122 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $239 | $134,325119 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $371 | $126,09579 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $292 | $114,898108 claims |
| Johnson & JohnsonXarelto | $150 | $67,53755 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $668 | $60,75452 claims |
| AbbVieLinzess | $747 | $26,29522 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $52 | $21,19614 claims |
| Esperion Therapeutics, Inc.Nexletol | $223 | $12,62711 claims |
| NovartisEntresto | $187 | $3,52920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in la Grange
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.